Positive development for Roche Covid-19 antibody test
Public Health England said the antibody test, developed by Swiss pharmaceutical company Roche, was a “very positive development”, Leading it to be approved in England.
The blood test looks for antibodies to see if a person has already had the virus and might now have some immunity. Until now, officials have said such tests are not reliable enough.
The government previously spent a reported £16m buying antibody tests which later proved to be ineffective whereas the Roche test was the first one to offer serious potential.
Finding antibodies that attack the coronavirus show that person has been infected in the past, but they do not prove they are protected against it in the future.
Public Health England said experts at the government’s Porton Down facility evaluated the Roche test last week, and they found that if someone had been infected, it gave the correct result 100% of the time.
Roche said if someone had not caught coronavirus then it gave the correct result more than 99.8% of the time.
It means fewer than two in 1,000 healthy people would be incorrectly told they had previously caught the coronavirus.
Health minister Edward Argar said the tests would mainly be used on those in the NHS and social care settings to begin with and could not give an exact date for when the testing could start.
Prof John Newton, national co-ordinator of the UK coronavirus testing programme, said: “This is a very positive development because such a highly specific antibody test is a very reliable marker of past infection.
“This in turn may indicate some immunity to future infection, although the extent to which the presence of antibodies indicates immunity remains unclear.”
Roche is believed to be in talks with the Department of Health and Social Care about possible use by the NHS in England, though other testing products are also being assessed.
Health officials in Scotland, Wales and Northern Ireland make their own decisions, but are likely to follow suit if England does adopt it.
The test already has approval from medical regulators in the EU and the United States.